NASDAQ:PTI - Proteostasis Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.02 +0.02 (+2.00 %) (As of 05/24/2019 04:00 PM ET)Previous Close$1.02Today's Range$1.00 - $1.0652-Week Range$0.97 - $10.38Volume734,472 shsAverage Volume1.63 million shsMarket Capitalization$52.12 millionP/E RatioN/ADividend YieldN/ABeta-1.06 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study. It has a collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts. Receive PTI News and Ratings via Email Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTI Previous Symbol CUSIPN/A CIK1445283 Webhttp://www.proteostasis.com/ Phone617-225-0096Debt Debt-to-Equity Ratio0.13 Current Ratio11.30 Quick Ratio11.29Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.84 million Price / Sales18.35 Cash FlowN/A Price / Cash FlowN/A Book Value$1.98 per share Price / Book0.52Profitability EPS (Most Recent Fiscal Year)($1.61) Net Income$-61,830,000.00 Net Margins-1,307.84% Return on Equity-84.01% Return on Assets-64.73%Miscellaneous Employees48 Outstanding Shares51,099,000Market Cap$52.12 million Next Earnings Date8/14/2019 (Estimated) OptionableOptionable Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions What is Proteostasis Therapeutics' stock symbol? Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI." How were Proteostasis Therapeutics' earnings last quarter? Proteostasis Therapeutics Inc (NASDAQ:PTI) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.28) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.11. The company had revenue of $5 million for the quarter, compared to the consensus estimate of $0.80 million. Proteostasis Therapeutics had a negative return on equity of 84.01% and a negative net margin of 1,307.84%. View Proteostasis Therapeutics' Earnings History. When is Proteostasis Therapeutics' next earnings date? Proteostasis Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Proteostasis Therapeutics. What price target have analysts set for PTI? 4 brokerages have issued 12-month price objectives for Proteostasis Therapeutics' stock. Their predictions range from $5.00 to $15.00. On average, they anticipate Proteostasis Therapeutics' stock price to reach $9.75 in the next twelve months. This suggests a possible upside of 855.9% from the stock's current price. View Analyst Price Targets for Proteostasis Therapeutics. What is the consensus analysts' recommendation for Proteostasis Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Proteostasis Therapeutics. What are Wall Street analysts saying about Proteostasis Therapeutics stock? Here are some recent quotes from research analysts about Proteostasis Therapeutics stock: 1. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and are lowering out 12-month PT to $14 from $21 on Proteostasis (due to lowering the probability of success on the program from 55% to 40%). This morning, the company announced and hosted a conference call to provide results from the low- and high-dose data from the triplet (PTI-801/808/428) trial. Additionally, the company announced data from the combination studies of on top of SYMDEKO. We feel the results were inferior to our projections, but believe data by year-end 2019 could make the case whether PTI’s internal drugs could be a competitive entrant in cystic fibrosis (CF)." (3/25/2019) 2. According to Zacks Investment Research, "Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts. " (3/15/2019) Has Proteostasis Therapeutics been receiving favorable news coverage? Media coverage about PTI stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Proteostasis Therapeutics earned a daily sentiment score of 1.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. Who are some of Proteostasis Therapeutics' key competitors? Some companies that are related to Proteostasis Therapeutics include Synlogic (SYBX), Chiasma (CHMA), Recro Pharma (REPH), Aldeyra Therapeutics (ALDX), Kala Pharmaceuticals (KALA), Syndax Pharmaceuticals (SNDX), Spero Therapeutics (SPRO), VBI Vaccines (VBIV), Hookipa Pharma (HOOK), Aeglea Bio Therapeutics (AGLE), CELYAD SA/ADR (CYAD), Affimed (AFMD), Evofem Biosciences (EVFM), Galectin Therapeutics (GALT) and Poxel (PXXLF). What other stocks do shareholders of Proteostasis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include BHP Group (BHP), Rite Aid (RAD), Idera Pharmaceuticals (IDRA), Micron Technology (MU), Clearside Biomedical (CLSD), Syndax Pharmaceuticals (SNDX), Resonant (RESN), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and Emblem (EMMBF). Who are Proteostasis Therapeutics' key executives? Proteostasis Therapeutics' management team includes the folowing people: Ms. Meenu Chhabra, Pres, CEO & Director (Age 47)Dr. Benito Munoz, Chief Scientific Officer (Age 57)Dr. Po-Shun Lee, Exec. VP & Chief Medical Officer (Age 50)Ms. Sandra Zimmerman, VP of Fin., Principal Financial Officer & Principal Accounting OfficerMs. Sheila Gilbride Wilson, Chief Operating Officer When did Proteostasis Therapeutics IPO? (PTI) raised $51 million in an IPO on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers. Who are Proteostasis Therapeutics' major shareholders? Proteostasis Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.89%), BlackRock Inc. (6.04%), Bain Capital Public Equity Management LLC (0.45%), Acadian Asset Management LLC (0.45%), Bailard Inc. (0.23%) and Algert Global LLC (0.13%). Company insiders that own Proteostasis Therapeutics stock include Cormorant Asset Management, Ll, Enterprise Associates 12 New, Franklin M Berger, Meenu Chhabra and Po Shun Lee. View Institutional Ownership Trends for Proteostasis Therapeutics. Which major investors are selling Proteostasis Therapeutics stock? PTI stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP and Bailard Inc.. Company insiders that have sold Proteostasis Therapeutics company stock in the last year include Meenu Chhabra and Po Shun Lee. View Insider Buying and Selling for Proteostasis Therapeutics. Which major investors are buying Proteostasis Therapeutics stock? PTI stock was acquired by a variety of institutional investors in the last quarter, including Bain Capital Public Equity Management LLC, Acadian Asset Management LLC, BlackRock Inc., Algert Global LLC, Hikari Power Ltd, State of Wisconsin Investment Board, Virtu Financial LLC and Jane Street Group LLC. Company insiders that have bought Proteostasis Therapeutics stock in the last two years include Enterprise Associates 12 New, Franklin M Berger and Meenu Chhabra. View Insider Buying and Selling for Proteostasis Therapeutics. How do I buy shares of Proteostasis Therapeutics? Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Proteostasis Therapeutics' stock price today? One share of PTI stock can currently be purchased for approximately $1.02. How big of a company is Proteostasis Therapeutics? Proteostasis Therapeutics has a market capitalization of $52.12 million and generates $2.84 million in revenue each year. The company earns $-61,830,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. Proteostasis Therapeutics employs 48 workers across the globe. What is Proteostasis Therapeutics' official website? The official website for Proteostasis Therapeutics is http://www.proteostasis.com/. How can I contact Proteostasis Therapeutics? Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected] MarketBeat Community Rating for Proteostasis Therapeutics (NASDAQ PTI)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 231 (Vote Outperform)Underperform Votes: 253 (Vote Underperform)Total Votes: 484MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote "Outperform" if you believe PTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: Growth and Income Funds Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.